Gulizia J M, Kandolf R, Kendall T J, Thieszen S L, Wilson J E, Radio S J, Costanzo M R, Winters G L, Miller L L, McManus B M
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, USA.
Am J Pathol. 1995 Aug;147(2):461-75.
In heart transplantation, long-term engraftment success is severely limited by the rapid development of obliterative disease of the coronary arteries. Data from various groups have been suggestive of a pathogenetic role of herpesviruses, particularly human cytomegalovirus, in accelerated allograft coronary artery disease; however, results are not yet conclusive. This study examines the hypothesis that human cytomegalovirus infection of allograft tissues is related pathogenetically and directly to accelerated coronary artery disease. Using in situ DNA hybridization and polymerase chain reaction, we examined particular coronary artery segments from 41 human heart allografts (ranging from 4 days to greater than 4 years after transplantation; mean, 457 days) and 22 donor age- and gender-comparable, coronary site-matched trauma victims for presence of human cytomegalovirus DNA. Human cytomegalovirus genome was detected in 8 of 41 (19.5%) allografts and in 1 of 22 (4.5%) control hearts. This difference in positivity was not statistically significant (P = 0.10). In the human cytomegalovirus-positive hearts, viral genome was localized to perivascular myocardium or coronary artery media or adventitia. Human cytomegalovirus genome was not detected in arterial intima of any allograft or control heart, although human cytomegalovirus genome was readily identified within intima of small pulmonary arteries from lung tissue with human cytomegalovirus pneumonitis. By statistical analyses, the presence of human cytomegalovirus genome was not associated with the nature or digitized extent of transplant arteriopathy, evidence of rejection, allograft recipient or donor serological data suggestive of human cytomegalovirus infection, duration of allograft implantation, or causes of death or retransplantation. Thus, our data indicate a low frequency of detectable human cytomegalovirus genome in accelerated coronary artery disease and do not support a direct role for human cytomegalovirus in vascular wall infection or in the development of accelerated coronary artery disease.
在心脏移植中,长期植入成功受到冠状动脉闭塞性疾病快速发展的严重限制。来自不同研究组的数据提示疱疹病毒,特别是人巨细胞病毒,在加速性同种异体移植冠状动脉疾病中具有致病作用;然而,结果尚无定论。本研究检验了同种异体移植组织的人巨细胞病毒感染在发病机制上与加速性冠状动脉疾病直接相关这一假说。我们使用原位DNA杂交和聚合酶链反应,检测了41例人类心脏同种异体移植(移植后4天至4年以上;平均457天)以及22例年龄和性别与供体匹配、冠状动脉部位匹配的创伤受害者的特定冠状动脉节段中人巨细胞病毒DNA的存在情况。在41例同种异体移植中有8例(19.5%)检测到人巨细胞病毒基因组,在22例对照心脏中有1例(4.5%)检测到。阳性率的这种差异无统计学意义(P = 0.10)。在人巨细胞病毒阳性的心脏中,病毒基因组定位于血管周围心肌、冠状动脉中膜或外膜。在任何同种异体移植或对照心脏的动脉内膜中均未检测到人巨细胞病毒基因组,尽管在患有巨细胞病毒肺炎的肺组织的小肺动脉内膜中很容易鉴定出人巨细胞病毒基因组。通过统计分析,人巨细胞病毒基因组的存在与移植性动脉病的性质或数字化程度、排斥反应证据、提示人巨细胞病毒感染的同种异体移植受者或供体血清学数据、同种异体移植植入持续时间或死亡或再次移植原因均无关。因此,我们的数据表明在加速性冠状动脉疾病中可检测到人巨细胞病毒基因组的频率较低,并且不支持人巨细胞病毒在血管壁感染或加速性冠状动脉疾病发展中起直接作用。